A study on clinico-immunological profile and treatment outcome of psoriatic arthritis by Ragunathan, R
 91 
A STUDY ON CLINICO-IMMUNOLOGICAL PROFILE AND 
TREATMENT OUTCOME OF PSORIATIC ARTHRITIS” 
 
Dissertation Submitted to 
THE TAMIL NADU DR.M.G.R.MEDICAL UNIVERSITY, 
CHENNAI- 600 032. 
 
In partial fulfillment of the regulation 
for the award of the degree of 
DM (RHEUMATOLOGY) 
BRANCH - IX 
 
 
 
MADRAS MEDICAL COLLEGE 
RAJIV GANDHI GOVERNMENT GENERAL HOSPITAL 
CHENNAI – 600 003. 
 
AUGUST 2013 
 92 
CERTIFICATE 
This is to certify that this dissertation entitled “A STUDY 
ON CLINICO-IMMUNOLOGICAL PROFILE AND 
TREATMENT OUTCOME OF PSORIATIC ARTHRITIS” 
presented here is original work done by Dr.R.RAGUNATHAN, 
DM Post Graduate in the Department of Rheumatology, Madras 
Medical College and Rajiv Gandhi Government General Hospital, 
Chennai- 600003 in partial fulfillment of the university rules and 
regulation for the award of D.M. Branch IX- Rheumatology, under 
my guidance and supervision during the academic period from 
2010-2013. 
 
 
 
 
 
Dr.V.KANAGASABAI, MD., 
Dean, 
Madras Medical College and  
Rajiv Gandhi Govt. General 
Hospital, 
Chennai – 600 003. 
Dr.S.RUKMANGATHARAJAN, MD., DM., 
FMMC., 
Professor and HOD, 
Department of Rheumatology, 
Madras Medical College and 
Rajiv Gandhi Govt. General Hospital, 
Chennai – 600 003. 
 93 
DECLARATION 
I, Dr.R.RAGUNATHAN hereby solemnly declare that this 
dissertation entitled “A STUDY ON CLINICO-
IMMUNOLOGICAL PROFILE AND TREATMENT 
OUTCOME OF PSORIATIC ARTHRITIS” was done by me in 
the Department of Rheumatology, Madras Medical College & Rajiv 
Gandhi Govt. General Hospital, Chennai-3 during January 2011 to 
December 2012 under the guidance and supervision of 
Prof.Dr.S.Rukmangatharajan, MD., DM., FMMC., This dissertation is 
submitted to the Tamil Nadu Dr.M.G.R.Medical University towards 
the partial fulfillment of requirement for the award of D.M., Degree 
in Rheumatology. 
 
 
Signature of the Candidate 
Date : 
Place : 
 94 
ACKNOWLEDGEMENT 
I express my heartful gratitude to the Dean, 
Dr.V.KANAGASABAI, MD., Madras Medical College & Rajiv 
Gandhi Govt. General Hospital, Chennai-3 for permitting me to do 
this study. 
I gratefully acknowledge and sincerely thank 
Prof.Dr.S.RUKMANGATHARAJAN, MD., DM., FMMC., 
Professor and Head, Department of Rheumatology, for his valuable 
suggestions, guidance, constant supervision and moral support 
without which this study would not have been possible.  
I am thankful to Dr.K.MUTHULAKSHMI, MD., Additional 
Professor for her valuable guidance in doing the Biochemical and 
Immunological workup of patients. 
I express my gratitude to Dr.T.N.TAMILSELVAM, MD., 
DM. Asst. Professor, Department of Rheumatology for the valuable 
guidance, advice and suggestions during the study.  
I am extremely thankful to Assistant Professors 
Dr.R.RAVICHANDRAN, MD., DCH., DM.,  Dr.S.BALAMEENA, 
MD., DCH., DM,  and Dr.D.THERASA MARY, MD., (Micro) and my 
 95 
FELLOW POSTGRADUATES for their constant support and 
advice during my study. 
I am extremely thankful to the Laboratory Personnel for 
their invaluable help in carrying out the immunological 
investigations without which, this work would not have been 
possible. 
I thank Physiotherapist, all Staff Nurses and all the 
Paramedical staff members in the Department of Rheumatology, 
Madras Medical College, Rajiv Gandhi Government General 
Hospital, Chennai for their full co-operation in conducting the 
study. 
I thank my parents, my wife and my son for their 
understanding and co-operation in completion of this work. 
Last but not the least, I owe my sincere gratitude to the 
patients and their relatives who co-operated for this study, without 
whom the study could not have been possible.  
 
 
 
 96 
INDEX 
S.NO CONTENTS PAGE NO. 
1.  INTRODUCTION 1 
2.  AIMS AND OBJECTIVES 3 
3.  REVIEW OF LITERATURE 4 
4.  MATERIALS AND METHODS 39 
5.  RESULTS OF THE DATA 45 
6.  DISCUSSION 63 
7.  CONCLUSION 73 
8.  BIBLIOGRAPHY  
9.  ANNEXURE 
A) PROFORMA 
B) MASTER CHART 
C) PATIENT CONSENT FORM AND 
INFORMATION SHEET 
D) ETHICAL COMMITTEE APPROVAL 
ORDER 
E) PLAGIARISM 
 
 
 97 
ABBREVIATIONS 
PsA  : Psoriatic Arthritis 
Anti-CCP : Anti cyclic citrullinated peptide 
ACPA : Anticyclic Citrullinated Peptide Antibody 
RF : Rheumatoid Factor 
HIV  : Human Immunodeficiency Virus 
HLA : Human Leukocyte Antigen 
KIR : Killer Immunog;obulim like Receptor 
TNF : Tumor Necrosis Factor 
IL : Interleukin 
SpA : SpondyloArthroathy 
TLR : Toll Like Receptor 
Th : T helper cell 
RA : Rheumatoid Arthritis 
MMP : Matrix MetalloProteinase 
TIMP : Tissue Inhibitor of Metallo Proteinase 
hsCRP : high sensitive C-Reactive Protein 
TGF : Transforming Growth Factor 
VEGF : Vascular Endothelial Growth Factor 
ANA : Anti Nuclear Antibody 
GRAPPA : Group for Research  and Assessment of 
Psoriasis and Psoriatic Arthritis 
OMERACT : Outcome Measures in Rheumatoid Arthritis 
Clinical Trials 
 98 
PASI : Psoriasis Activity and Skin Score 
BASDAI : Bath Ankylosing  Spondylitis Disease 
Activity Index 
ESR : Erythrocyte Sedimentation Rate 
DMARD : Disease Modifying  Anti Rheumatic Drug 
RCC : Rheumatic Care Centre 
CASPAR : Classification criteria for Psoriatic Arthritis 
ILAR : International League Against Rheumatism 
ASO : Anti Streptolysin- O 
ELISA : Enzyme Linked Immuno Sorbent Assay 
SJC : Swollen Joint Count 
TJC : Tender  Joint Count 
MASES : Maastricht Ankylosing Spondylitis 
Enthesitis Score 
 
 
 
   
 
 
 1 
INTRODUCTION 
  Robert Willan, the British dermatologist described psoriasis 
as an independent disease in 18-th century.
1
The  French  Physician  
Baron  Jean  Louis  Alibert  first  described the association   
between  the  psoriasis  and psoriatic arthritis   in 1918. 
2 
Initial clinical features of PsA were described first by Wright 
V et al in 1959 and along with Moll they published the first 
classification criteria in 1973.
3 
Psoriatic  arthritis  was included  as  
a  distinct arthritis  in  the classification  of  rheumatic  diseases  in 
1964  by  American Rheumatism Association.
 
Psoriatic arthritis is one of the diseases of SpA family and 
defined as inflammatory arthritis occurring in patients with 
psoriasis and negative test for rheumatoid factor commonly. It is a 
progressive and disabling disease and often associated with 
increased morbidity.
4 
According to one prospective study  by Kane D et al, 
psoriatic arthritis constituted 13 % of new patients attending early 
arthritis clinic and progressive erosive change occurs in around 50 
% of patients in the first few years.
5 
 2 
The exact prevalence of psoriasis and psoriatic arthritis is not 
known and the prevalence of psoriasis in general population is 
around 1 to 3 %. The incidence of arthritis in patients with psoriasis 
is between 5 and 7 %.
 
There are only few studies in psoriatic arthritis in India 
especially the immunological profile like anti-CCP antibodies in 
psoriatic arthritis, correlation of skin and arthritis. So we took this 
study to correlate the skin disease and arthritis as well as to study 
the immunological profile of patients with psoriatic arthritis.  
 3 
AIMS AND OBJECTIVES 
1) To study the clinical profile of patients with psoriatic 
arthritis. 
2) To assess the correlation between skin disease and arthritis in 
patients with psoriatic arthritis. 
3) To study the immunological profile of patients with psoriatic 
arthritis. 
4) To assess the outcome of patients with psoriatic arthritis.  
 4 
REVIEW OF LITERATURE 
EPIDEMIOLOGY 
The prevalence psoriasis and psoriatic arthritis have shown 
ethnic and geographic variation and more common in colder north 
(Europe) when compared tropics.   The prevalence of arthritis in 
patients with psoriasis is about 8.47 percent according to a clinical 
study from South India.
7
 The prevalence to cutaneous psoriasis in 
Europe varies from 0.6 to 6.5% and in US around 3.15% .
8
    The 
exact prevalence of PsA status is unknown and according to various 
studies it ranges from 0.3 to 1% of population .The prevalence of 
psoriatic arthritis in patients with cutaneous psoriasis varies from 
7% to 42%in number of studies.
6  
 
 No sex predilection has been documented unlike other 
inflammatory arthritis and few studies have shown male 
preponderance.
9
 Development of PsA may occur at any age but 
majority of patients are in the 3
rd
 or 4
th
 decade. 
 
Wide variation in the prevalence in different population is 
mainly due to heterogeneity of the disease and lack of widely 
accepted diagnostic criteria for psoriatic arthritis. Because most 
epidemiological studies have been performed in Caucasians the 
 5 
racial and ethnic associations is not well known. The risk of 
development of arthritis is  more in patients with scalp psoriasis, 
nail dystrophy and intergluteal or perianal lesions .
10
  
The poor prognostic factors are 
11 
1) Erosions and polyarticular pattern at onset
 
2) Extensive skin involvement. 
3) Strong family history of psoriasis  
4) Disease onset before 20 years.  
In majority of patients (approximately 67% of patients with 
PsA) skin disease precedes arthritis. Joint manifestations precede 
the cutaneous disease in around 15% of patients and both these 
condition occur within 12 months each other in the remainder 
population.
12 
Cutaneous psoriasis precedes the onset of arthritis by 9 to 10 
years in patients with type 1 psoriasis (onset of psoriasis before 40 
years).In patients with type 2 psoriasis (onset after 40 years) joint 
disease usually develops within one year of skin disease.
12
 There is 
increased susceptibility to PsA with HIV infection and several 
studies showed the prevalence of 0.4 to 2%.  These groups of 
 6 
patients have severe skin and polyarticular disease often occurring 
simultaneously .
13
 
PATHOGENESIS OF PSORIATIC ARTHRITIS  
GENETIC SUSCEPTIBILITY  
Based upon familial clustering of the disease, the propensity 
of PsA is influenced by heredity. The risk of development of PsA 
among first degree relatives of PsA is around 15% and for 
cutaneous psoriasis is 30-40%.  The recurrence risk ratio (λ) of PsA 
in the sibling was found to be more than 27 and in psoriasis 4 to 11 
.14
 According to twin studies ,the concordance rate for dizygotic 
twins is between 21 and 23 % and for monozygotic twins 62 -
70%.
15
 Several studies have demonstrated that PsA is a polygenic, 
multi factorial disease with many susceptibility loci.  
Based upon the linkage association studies the following loci 
are found to be associated with PsA. 
I. HLA Association 
1) HLA cw 06 carriers are associated with long time interval 
between the onset of psoriasis and PsA (Type 1 psoriasis). 
2) HLA B- 38 and B-39 carriers have more peripheral arthritis. 
3) HLA B-27, cw2 and   DR w52 associated with spinal disease.  
 7 
II. MICA A 9 Polymorphisms: MHC Class I chain related gene 
A (MICA)   is also associated with increased susceptibility 
independent of HLA cW6  . 
III. Other Loci associated with PsA : 
16 
Gene Chromosomes Odds Ratio 
KIR Alleles 5q33 1.1 
TNF-308 A Alleles 6p21 1.96 
IL-12 B 5q 33 1.1 
IL-23 R 1p 31 1.70 
IL-1 Gene cluster 2q 13 1.82 
IL 2/IL 21 4q 27 1.37 
Susceptibility for psoriasis 
1) HLA Region: Strong association between cuteneous psoriasis 
and HLA-C region has been recognized.  Elder demonstrated 
the psoriasis susceptibility region in MHC region – HLA cW6 
often with linkage disequilibrium  with HLA-B 57, HLA-B 
37, HLA B13 .
17
 
2) Non MHC Susceptibility Regions: PSORS regions on 
chromosome 4, 6, and 17 have been identified as non -HLA 
susceptibility regions based on whole genome scans. 
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ENVIRONMENTAL RISK FACTORS 
1. Infection 
The link between post streptococcal tonsillitis and subsequent 
guttate psoriasis especially in young patients with HLA cW6 
positivity has been demonstrated.
18
The inflammatory process 
stimulated by super antigens and molecular mimicry between 
cutaneous antigens and streptococcal antigens are the explanation 
for this pathology.  
2. Other  risk factors  
 HIV Infection 
 Rubella Vaccination 
 Recurrent oral ulcers 
 Stressful life events 
 Obesity 
3. Deep Koebener Phenomenon 
Trigger of episodes of joint inflammation due to joint 
locomotion is also found to be a precipitating event and in one 
study 24.6 % of patients with psoriatic arthritis have been shown a 
traumatic event before the onset of arthritis.  
19 
 9 
4. Smoking 
The temporal relationship between psoriasis, psoriatic 
arthritis and smoking has been demonstrated.  It has been reported 
that history of smoking prior to onset of psoriasis, the duration 
between the psoriasis and the arthritis development decreases .The 
interval increases with smoking after onset of psoriasis.
20 
IMMUNOPATHOLOGY 
Cutaneous Psoriasis  
Interaction between innate and acquired  immunity plays a 
major role in the formation of psoriatic plaques .
21
  Interferon α 
plays a major role in psoriasis and up-regulation of IFN α signature 
genes by nucleic acids (both DNA and RNA) showed the central 
role of interferon. Binding of DNA released by stressed or 
apoptotic keratinocytes to LL 37 – cathelicidin  an antibacterial 
peptide from kerotinocytes forms a complex. This complex binds to 
TLR 9 of plasmocytoid dentritic cells which in turn involved in  the 
release of interferon α.22  
Activated dermal dentritic cells by IFN α moves to the 
regional lymph nodes promote T cell differentiation to Th1 and 
Th17 cells. These cells move to the dermis via lymphatic and blood 
vessels.  In the dermis Th1 cells release gamma Interferon and TNF 
 10 
and Th17 cells produce IL1, IL 17, IL 22 and TNF.   IL 22 
stimulates keratinocytes proliferation and cathelicidin production.    
Keratinocytes secrete IL 1, IL 6, TNF and chemokines.  Dentritic 
cells also induce proliferation of T lymphocytes and release IL 23 
which is essential for survival of Th 17 cells. 
 Cross talk between the endothelial cells, fibroblast and 
keratinocytes lead to tissue remodeling and matrix molecule 
deposition and also there is marked angiogenesis in the dermis 
.23 
Cutaneous lesions are characterized by epidermal hyperplasia, 
mono nuclear leukocyte infiltration in the papillary dermis, stratum 
corneum with neutrophils and dendrite cells .
24
 Infiltration in 
epidermis with CD 8 + T cells and dermis with mixture of CD4 + 
CD 8 + cells occur in plaques.  
Synovium 
Prominent and striking vascular changes in the synovium are  
the most important aspect of psoriatic joint inflammation.  Both 
light and electro-microscopy reveal endothelial cell swelling  with 
marked thickening of the vessel wall, higher number of infiltrating 
CD163 + macrophages,  increased number of vessels and more 
tortuous vascularity in the synovium of the psoriatic arthritis when 
compared to RA Synovium .
25 
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Synovial biopsy reveal infiltration of inflammatory T, B cells 
and monocytes in a similar frequency as RA and digital image 
analysis of biopsy showed PsA synovium had lower number of 
plasma cells, but similar expression of  TNFα, IL 1 β, IL6, IL18, 
MMPs and adhesion molecules.Increased in neutrophil Infiltration 
in Psoriatic arthritis synovial tissue compared to RA was also 
identified .
26 
Summarizing the histological appearance of PsA synovium 
marked vascularity with increased neutrophilic infiltrates and fewer 
T lymphocytes infiltrates are characteristic findings.  
Enthesial Sites 
Increased CD 8 + T cells expression was observed from 
enthesial sites in patients undergoing joint replacement surgery for 
psoriatic arthritis .
27
Biopsy from ethesitis site shows increased 
vascularity and cellularity predominantly macrophages infiltration.  
Nail Disease 
Nail lesions are more prevalent the psoriatic arthritis than in 
cutaneous psoriasis without arthritis. Presence of enthesis of DIP 
including tendon, lateral collateral ligaments are attached to both 
nail and adjacent periosteum and this explains the nail lesions more 
common in psoriatic arthritis .
28 
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Cartilage Destruction and MMP:  
 Up-regulation of MMP in PsA synovium is evidenced by 
immuno histochemical studies showing MMP 9 localized to blood 
vessels cell wall where as MMP 1, 2, 3, TIMP 1 and TIMP 2 in the 
cellular and interstitial staining in synovial lining.   Elevated MMPs 
to TIMP 1 in synovial tissue lead to cartilage destruction. Serum 
levels of MMP 3 serve as a biomarker of PsA activity .
29 
The biomarkers for arthritis in patients with psoriatic arthritis are
30 
1) CPII: C2C ratio –    C- propeptide of type II collagen 
:collagen fragment neoepitopes. 
2) Osteoprotegerin 
3) MMP-3 
4) hs-CRP 
Bone Remodeling: 
31 
Radiographic findings of PsA show altered bone modeling as 
bone resorption and new bone formation.  Accumulation of large 
multi nucleated osteoclast in the resorption pits is demonstrated in 
PsA pannus bone junction.  Upregulation of RANKL protein and 
decreased expression of osteoprotogerin were detected in synovium 
of PSA patients.  
 13 
TGF β and VEGF are very important for new bone formation 
and BMP 2 and BMP 7 are up regulated at the areas of new bone 
formation.  
Involvement of wnt   Pathway and balance between wnt 
antagonist dickop 1 (DKK1) are very important in the disordered 
bone re modeling in PsA 
Cytokines involved:
32 
The imbalance of pro inflammatory and anti inflammatory 
cytokines is responsible for synovitis. 
Higher levels of Th1 Cytokines   IL 2, Interferon γ in the 
synovium of PsA  than in RA synovium are demonstrated.  IL 1 and 
TNF are elevated in skin, synovium and joint fluid of PsA are also 
noted.  
Patients with TNF α 308 Allele with higher levels of TNF 
have more erosions than the patients without this allele.  Activated 
IL 23 / Th 17 pathway in patients with PSA is evidenced by 
increased levels of IL 17 in synovial fluid as well as increased 
circulating levels of Th 17 cells.   
 14 
Involvement of both innate and acquired immunity with 
prominent role for Th 1, Th 17 cells and TNF are important in the 
pathogenesis of psoriatic arthritis. 
PSORIASIS 
Psoriasis is a chronic, complex, multifactorial inflammatory 
skin disease due to increased proliferative of keratinocytes in the 
epidermis with exaggerated epidermal cell turnover rate.  It 
commonly manifests as a well demarcated erythematous plaque 
with silvery white scales on the elbow, scalp, knees, umbilicus 
intergluteal region and lumbosacral areas.     
Signs and symptoms of psoriasis are
32 
1) Acute onset of small areas of red scaly lesions [macules, 
papules, plaques] 
2) Worsening of longstanding erythematous scaly plaques. 
3) Pain – especially in erythrodermic type in areas of 
traumatized plaques.     
4) Pruritis – especially in guttate psoriasis. 
5) Dystrophic nails. 
6) Blepheritis and conjunctivitis 
 15 
7) Recent streptococcal and viral infection 
8) Trauma (Koebner phenomenon) 
9) Precipitating drugs – antimalarials ,Beta blockers. 
TYPES OF PSORIASIS 
Psoriasis vulgaris (or) chronic stationary psoriasis:  
a) Most common type 
b) Involve scalp, retro auricular regions, extensor surfaces, 
umbilicus, genitals and lumbosacral areas. 
Plaque Type: 
Affects the extensor surface of knees, elbows, scalp and 
trunk.   
Inverse Psoriasis: 
a) Occurring over the flexural (or) intertriginous areas  
b) Scaling is minimal. 
Guttate psoriasis:  
a) Small, erythromatosquamous plaques and papules 
b) In children 
c) Over the trunk 
 16 
d) Sudden onset after two to three weeks of respiratory infection 
with beta hemolytic streptococci. 
Pustular psoriasis 
a) Generalized pustular psoriasis. 
b) Localized  
i. Acrodermatitis continua suppurativa 
ii. Extensive lakes of pus merging to disseminated 
erythematous areas.   
Erythrodermic psoriasis 
Both vulgaris and pustular forms may progress to psoriatic 
erythroderma involving whole body.   
Scalp psoriasis 
Occurs in 50% of patients. 
Nail psoriasis 
Occurs in 20 – 50% of patients with psoriasis 
Nail disease in psoriasis is divided into nail bed and nail 
matrix lesions. Nail matrix lesions present in nail plate are pitting, 
red spots in lunula, leukonychia and crumbling.  The nail bed 
 17 
changes are oil drop discoloration, splinter haemorrhages, 
hyperkeratosis, and onycholysis.  
 Mucosal (or) oral psoriasis 
Presenting as severe ctheilosis with extending into surround 
skin.   
Eruptive psoriasis 
Involving upper trunk and upper extremities especially in 
younger patients.   
Palmoplantar psoriasis 
PSORIATIC ARTHRITIS 
Classification criteria: 
For the diagnosis of psoriatic arthritis, earliest criteria by 
Moll and Wright is the simplest   and   was used previously .
3 
Moll and Wright criteria are, Presence of psoriasis and  
1. Inflammatory arthritis [peripheral, spondilitis or 
sacroiliitis] 
2. absence of Rheumatoid factor  
The CASPER criteria is  the  most  validated  and  has high 
sensitivity and specificity of 98.7percent ,91.4 percent  respectively 
for the diagnosis of early as well as late PsA .
34 
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The diagnosis of PsA is made in the presence on 
inflammatory articular disease [joint, enthesis or spine] and at least 
three points  
 Current psoriasis (2points), H/O psoriasis (1) or family H/O 
psoriatic skin disease (1). 
 Nail changes (1) - pitting, onycholysis and hyperkeratosis. 
 Negative RF (1 ) 
 Dactylitis ( 1) current or previous episode. 
 Juxta-articular new bone formation by X-ray (1). 
Articular involvement 
According to Moll and Wright, five types of articular 
involvement are 
1) Predominantly DIP involvement 
2) Asymmetric oligo-arthritis 
3) Symmetric polyarthritis like R.A. 
4) Arthritis mutilans 
5) Predominant axial involvement. 
 19 
This subtypes classification has limitations practically 
because high degree of overlap between the categories and axial 
involvement can be detected in nearly one third of patients and 
predominant spondylo arthropathy occurs in minority of cases.
35
and 
also duration of the disease at the time of study influences the 
pattern arthritis. Involvement of spine also increases with duration 
of the disease. After the correction of total number of joints 
involved ,there was no difference in symmetricity of arthritis 
observed between  PsA and RA when comparing early and late  RA 
and PsA. 
36 
DIP arthritis 
DIP predominant subgroup comprises 1- 16 percent of 
psoriatic arthritis and this pattern occurs in early course of the 
disease 
.37
This type is commonly associated with nail dystrophy and 
dactylitis. DIP joints are involved frequently in with psoriasis 
(3.9percent) than in patients without psoriasis (0.3) .
38 
Asymmetric oligoarthritis 
The frequency of this pattern at onset ranges from 11 to 70 
percent. Majority of patients will progress to additional joint 
inflammation in the disease course. Lower limb arthritis and hand 
 20 
joint involvement are more common and show male 
predominance.
35 
Symmetric Polyarthritis 
This pattern has female predominance and prevalence of this 
pattern in PsA 3% at onset and leads to occur during longer disease 
course and these groups of patients have more erosive damage.
39 
The typical features of psoriatis polyarthritis are
8 
1) ―ray pattern‖ of distribution 
2) more degree of erythema 
3) lower level of tenderness 
4) enthesitis 
5) spine involvement. 
6) More proportion for involvement of interphalangel joint of 
thumb. 
 According to Danda et al,there is 84% chance of having 
psoriatic arthritis if there is disproportionate swelling of 
interphalangeal joint of the thumb.
40 
 
 21 
Arthritis Mutilans 
The end stage of destructive erosive arthritis with 
disorganized joints and subluxation is called arthritis mutilans and 
leading to digital telescoping called opera glass fingers.  
The prevalence of arthritis mutilans is <5% and has female 
predominance and associated with long standing disease.
41 
Spondyloarthropathy 
The spondyloarthropathy predominant subtype is uncommon 
and constitutes 5% of patients and radiographic evidence of 
involvement of axial spine in 20 to 40% of PsA patients.  The 
involvement of cervical spine is common and strong association 
with HLA – B27 noted .42  Two main types of cervical spine 
involvement are ankylosing type like primary AS and erosive or 
inflammatory type leading to AA or sub axial instability.   
The presence of asymmetric sacroiliitis, lower incidence of a 
zygapophyseal ankylosis and higher proportion of cervical spine 
involvement are differentiating features from primary AS.  
Dactylitis 
The swelling of entire digit due to flexor tenosynovitis and 
synovitis occurs in     30 – 40% of cases during the course of the 
illness and commonly involves feet.   
 22 
Enthesitis 
Inflammation at the site insertion of tendon, ligament, fascia, 
capsule in to the periosteum of the bone is called ―enthesitis‖ and 
occurs in 20 to 40% of PsA patients during the course of the disease 
and presenting feature in approximately 4% of cases.  The common 
sites are tendoachilles; planter fascia and ligamentous insertions to 
bony pelvis.   
Peripheral edema 
Asymmetric and predominantly lower limb peripheral edema 
can occur as a presenting feature or during the course of the illness.  
Extensor tenosynovitis and lymph edema are proposed 
mechanisms.
43 
SAPHO Syndrome 
The components of this syndrome are synovitis, acne, 
pustulosis, hyperostosis, osteiitis occur in around 30% of patients 
and 67% of SAPHO patients have palmo plantar psoriasis or 
psoriasis vulgaris.
44 
Other uncommon features are 
Chronic multifocal recurrent osteomyelitis 
Onycho-pachydermo periostitis     
 23 
Nail disease 
Close association between nail and joint disease in patients 
with PsA have been demonstrated.  The frequency of nail lesions in 
psoriasis without arthritis and psoriatic arthritis are 20 – 40% and 
60 – 80% respectively.  The onset of nail changes occurs usually 1 
to 2 years before the onset of joint disease.
45
 Patients with DIP 
arthritis have more nail changes.  These are ridging, pitting, 
onycholysis, and hyperkeratosis.  The presence of >20 pits 
differentiates patients with PsA from those of RA with psoriasis.
46
  
JUVENILE PSORIATIC ARTHRITIS 
Juvenile PSA in which onset of arthritis before 16
th
 birthday 
constitutes less than 10% of chronic arthritis of children.  Onset of 
arthritis precedes cutaneous psoriasis in 50% of cases.
47 
The characteristic features of Juvenile PSA
 
1) Female preparedness 2 to 3:1 
2) Frequently mono or polyarthritis – commonly knee is the first 
affected joint. 
3) Higher prevalence of chronic uveitis around 10 – 14%  often 
with ANA positivity. 
 
 24 
Two subgroups in Juvenile PSA 
1) Onset around 2 years 
 Female predominance 
 Low prevalence of cutaneous psoriasis 
 More oligoarticular pattern 
 High prevalence of dactylitis 
 60% ANA positivity 
2) Onset around 9.5 yrs: 
 More axial disease, polyarticular pattern and enthesitis.  
Overall prognosis of juvenile PsA is good and persistent 
disease activity and residual disability occur in 10% to 15% of 
patients. 
Proposed diagnostic criteria for Juvenile PSA accounting to South 
wood and Associates:
47 
Definite: Arthritis onset before 16 years of age and plus either 
psoriasis (or)   Three minor criteria 
 Nail Pitting 
 Psoriasis like rash 
 25 
 Dactylitis 
 Family history of psoriasis 
Probable Juvenile PSA: Arthritis onset before 16 yrs of age 
plus two minor criteria. 
ILAR classification criteria for juvenile PsA are 
48 
Arthritis and psoriasis (or) arthritis pius two of the following three 
1) Psoriasis in a 1-st degree relative 
2) Nail changes 
3) Dactylitis 
Extraarticular features 
1. Ocular inflammation commonly in the form of conjunctivitis. 
Prevalence of iridocyclitis is around 7 to 25% and more bilateral 
than in primary AS often in patients with axial involvement.  
2. Inflammatory bowel (asymptomatic). 
3. Urethritis 
4. Oral ulceration 
5. Aortic valve disease. 
6. Hyperuricemia. 
7. Raised ASO titer 
9
 
 26 
Auto antibodies in PSA 
Rheumatoid factor positivity has been found in 5 – 10% of 
psoriatic arthritis patients.
42
  Anti cyclic citrullinated peptide 
antibodies are demonstrated 6 to 10% of patients with psoriatic 
arthritis and it is associated with female preponderance and 
polyarticular pattern, DTP involvement, enthesitis and deformities 
and functional impairment of peripheral joints.
49
 Antinuclear 
antibodies are positive in significant titer in around 10 – 14% of 
patients with psoriatic arthritis and there was no significant 
difference among the patients with ANA positive PsA and ANA 
negative PsA.
50 
IMAGING IN PSORIATIC ARTHRITIS 
CONVENTIONAL RADIOGRAPHY 
Peripheral joints 
  Psoriatic arthritis is charecterised by both osteoproliferative 
and osteodestructive lesions. Joint involvement is often 
oligoarticular, asymmetric and ray pattern. Hand joints are involved 
more commonly than feet with the ratio of 2:1. DIP joints often 
first affected, followed by PIP,MCP joints. 
Proliferative changes: periosteal new bone formation along the 
shaft of metacarpal and metatarsals. 
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 If erosion occurs near this,it is termed ―whiskering‖.51 
 Ivory phalanx‖ marked periosteitis especially great toe.  
 New bone formation at enthesial sites 
Osteodestructive changes 
 Ill-defined,irregular,marginal erosions more common in DIP 
joints rather than wrists.
52 
 More common in polyarthritis and long standing disease.  
 Prevalence of erosions between 35 and 70 percent.
53 
 Pencil in cup deformity especially in mutilans variant.  
Other features are 
 Soft tissue swelling,joint space narrowing 
 Ankylosis. 
 
Axial skeleton:
54 
1) Asymmetric sacroiliitis often bilateral 
2) Spotty,asymmetric involvement of spine most frequently in 
the cervical region. 
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3) Chunky syndesmophytes (nonmarginal) or paraspinal 
ossification distributed throughout the spine in asymmetric 
fashion. 
4) Zygapophyseal joint involvement less severely and less 
frequently. 
5) Squarring of vertebra and corner osteitis are very uncommon. 
6) Atlantoaxial subluxation rarely. 
MAGNETIC RESONANCE IMAGING 
MR imaging clearly demonstrates the extent and severity of 
joint pathology.   Subclinical involvement of peripheral and axial 
joints as well as underlying pathology is revealed by MR imaging. 
It is a very sensitive tool for the detection of spondylitis and 
sacroiliitis in the pre erosive phase.
55 
The pathgnomonic of 
psoriatic arthritis is bone edema especially in the diaphyseal 
region.Fat suppressed  T2 weighted images of the periarticular  soft 
tissues i.e. enthesitis are usually the first changes in the psoriatic 
arthritis. 
Charecteristic MRI features of psoriatic arthritis are bone 
marrow edema, periosteitis, enthesitis, dactylitis, tenosynovitis, 
synovitis, onychopathy and spondylitis. 
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ULTRASONOGRAPHY  
Doppler ultrasonography and high frequency transducers are 
very much useful for the assessment of dactylitis and enthesitis. 
These are much more sensitive than MRI in the detection of early 
enthesitis.
56 
MEASUREMENT OF DISEASE ACTIVITY IN PSORIATIC 
ARTHRITIS 
Evaluation of clinical domains of PSA from peripheral 
arthritis to spondylitis is necessary for assessment of disease 
activity.  Accurate measurement of disease activity is necessary for 
monitoring the treatment response and for observational studies of 
psoriatic arthritis  and research trials.
57 
According to GRAPPA-OMERACT recommendations, the 
following are the core set of domains which are to be assessed and 
measured in the patients with psoriatic arthritis.
58 
Domains included in the inner circle of core set are: 
1) Skin activity 
2) Pain 
3) Peripheral joint activity 
4) Patient global assessment 
5) Health related quality of life 
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6) Physical function    
Domains in the outer circle are 
1) Spinal disease 
2) Nails 
3) Dactylitis 
4) Enthesitis 
5) Physician global 
6) Fatigue 
7) Nail 
8) Radiology 
Domains which are placed for research studies 
1) MRI 
2) CT 
3) Ultrasound 
4) Participation 
5) Tissue analysis    
Peripheral joint assessment 
ACR response criteria and Psoriatic arthritis response criteria 
(PsARC) are the instruments commonly used to assess the 
treatment efficacy and in follow up studies.  The PsARC measures 
swollen joint count (SJC), tender joint count (TJC), Physician 
global assessment (on a 1 – 5 Linkert assessment scale) patient 
global assessment (on 1 – 5 Linkert scale).59 
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Psoriatic arthritis response criteria is detected with reduction 
in SJC and or TJC of >30% along with reduction of at least one unit 
in Linkert scale of Pt.GA (or)PGA.  The patient is said to fulfill 
PsARC when there is improvement in two of four items (one must 
be joint the count) without worsening of any measure.  
Joint count of 66 swollen joints and 68 tender joints are used 
for assessment because it includes a majority of joints involved in 
PsA.
60
 The 66 swollen counts included are TMJ, sternoclavicular, 
acromioclavicular, shoulder, elbow ,wrist, MCP, PIP, DIP joints of 
both upper limbs as well as both, knee, ankle, subtalar, MTP and IP 
joints of the toes and for 68 tender joint limb includes both hip 
joints.   
Assessment of skin disease 
Cutaneous disease is a major feature of psoriatic arthritis and 
is responsible for low quality of life.  The evaluation of skin 
involvement is by two methods: 
1) Subjective – Patient and physician global 
2) PASI.
61
 
PASI score was studied extensively and validated tool with 
good reliability and reproducibility.  The limitations of PASI are 
 32 
less sensitivity to change and decreased performance especially in 
patient with less degree and extent of skin involvement  of less than 
10% of body surface area and poor correlation with quality of life 
measures .  PASI is said to be gold standard despite its limitations.   
PASI – morphologic scoring of psoriasis is done by 
evaluating three parameters namely erythema, induration and 
scaling and these are graded into four grades according to the 
severity: 0 – Nil; 1 – mild; 2 – moderate; 3 – severe;             4 – 
very severe.  Addition of these scores for the individual sites is 
multiplied by the grading for area wise percentage of involvement 
including head and neck, upper limbs, trunk, lower limbs.  
The grading of area of skin involvement with psoriasis in 
each area: 
0 - No 
1 - <10% of involvement 
2 - 10 – 29% 
3 - 30 – 49% 
4 - 50 – 69% 
5 - 70 – 89% 
6 - >90% 
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For individual site value A to D is derived by multiplying the 
grade of area involvement and morphologic score with correction 
factor of 0.1, 0.2, 0.3 and 0.4 for head and neck, upper limb, trunk 
and lower limbs respectively.   
PASI = A + B + C + D 
A = 0.1 X [Eh + Ih + Sh] x area grading 
B = 0.2 X [Eu + Iu + Su] x area grading 
C = 0.3 X [Et + It + St] x area grading 
D = 0.4 X [El + Il + Sl] x area grading 
Correction factor individual region used because body regions 
– head and neck, upper limb, trunk and lower limbs represent 10%, 
20%, 30% and 40% of total body surface area respectively.   
PASI score varies between 0 – 72 and; in mild disease <10, 
moderate disease 10 – 40. 
Assessment of Dactylitis  
Sausage finger (or) dacylitis is a characteristic feature in 
patient with severe and active psoriatic arthritis and manifesting as 
uniform swelling of entire digit due to combination of 
tenosynovitis, enthesitis, synovitis and soft tissue edema.
62 
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Clinical assessment of dactylitis by two methods:  
1) Presence or absence 
2) Leeds Dactylitis Index.
63
 
Leeds dactylitis index (LDI) measures both circumference 
and tenderness of the swollen figure and difference of 10% in 
circumference between the involved and non-dactylitic digit is 
taken as cut off.  LDI is a valid tool for assessment of dactylitis and 
has good inter observer reliability. 
Enthesitis assessment 
It is defined as the inflammation at the site of insertion of 
ligament, fascia, tender and capsule into the periosteum of the bone 
and is a common feature PSA and prevalence is around 30 – 50%.  
The instruments used in enthesitis assessment are Newcastle 
Enthesitis Index (NEI) by Mander
64
and Maastricht AS enthesitis 
score(MASES).
65 
MASES is a valid, simple and reliable tool and includes 13 
sensitive and specific sites of enthesitis and given the score of 0 
and 1 for tenderness.  The sites are  spinous process of fifth lumber 
vertebra, proximal Achilles insertion on both sides,bilateral iliac 
crests and anterior and posterior iliac spines, first and seventh costo 
chondral junction on both sides. 
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Spine assessment 
Involvement of spine in PsA is heterogeneous and less severe 
than in primary ankylosing spondylitis and varies from 40 – 51%.  
The measurement of disease activity by BASDAI, functional ability 
by BASFI and assessment of spinal mobility by BASMI.
66
  
BASDAI is combination of set of visual analogue scales of 6 
items including pain, stiffness and fatigue.     
BASDAI correlates well with the patients perception of 
disease activity, but does not discriminate between peripheral and 
spine disease activity .
67 
Patient Global Assessment 
This is included in the inner circle of corset domains for 
disease assessment.  This is useful to assess the patient discomfort 
and is more patients oriented clinical assessment.  This is included 
in the assessment measures like PsARC, ACR response criteria and 
Disease Activity Score.  PGA is measured by means of either visual 
analogue scale (0 to 100) for joints and  5 point linkert scale  by 
asking question as ―How would you rate the symptoms over the 
past 7 days‖ and 0 in VAS or linkert scale as no symptoms and 100 
or 5 for very severe symptoms by using drawing vertical lines in 
VAS  and  making circle in linkers scale.
68
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Physician Global Assessment 
This is measured in the identical manner to PtGA using 
Linkert scale for PsARC.   
Assessment of Nail changes 
The commonly used tools for nail disease assessment are 
NAPSI 
69
and modified NAPSI.
70
 The m-NAPSI is a simple, 
objective instrument for psoriatic nail assessment.   
Minimal Disease Activity:
71 
This concept is developed by Coates et al and reviewed by 
OMERACT towards the ‗treatment to target‘ in patients with 
psoriatic arthritis and the patient is said to have MDA if they have 
5 of 7 desired criteria namely  
 Swollen joint count    <1, 
 Tender joint count <1, 
 PASI <1, (or)body surface area <3,  
 PGA VAS <20,  
 Patient pain VAS <15,  
 Tender entheseal point <1  
 HAQ <0.5. 
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OUTCOME OF PSORIATIC ARTHRITIS  
 Psoriatic arthritis is a progressive disease in major 
proportion of patients and in spite of clinical improvement, 
progressive erosive disease was observed in 47% of patients during 
2 years of follow up, in one study.
72 
Markers (or) predictive factors for the progressive disease are: 
1) Polyarticular pattern at onset (five joint effusions or more)
73
 
2) HLA DQ Cw3 
3) HLA B39 
4) HLA B27 
Long term outcome assessment studies have demonstrated 
increased morbidity and mortality in patients with psoriatic 
arthritis.  In one study deforming arthritis was documented in 40 – 
57% of patients, spinal involvement in 20 – 40% of patients and 
11% to 19% were disabled and there is increased mortality when 
compared to background population.
74 
Increased mortality rate in patients with psoriatic arthritis and 
standardized mortality ratio of 1.36 were shown in a hospital cohort 
study.
75 
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The common causes of mortality in patients with psoriatic 
arthritis are respiratory disease, neoplasia, cardiovascular disease 
and predictors of mortality are increased ESR, radiologic damage, 
prior use of DMARDS and steroids.
76 
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MATERIALS AND METHODS 
PLACE OF THE STUDY  
Department of Rheumatology, Rajiv Gandhi Govt General 
Hospital & Madras Medical College, Chennai-3. 
DESIGN OF THE STUDY  
Prospective analytical study 
PERIOD OF THE STUDY 
2 years -From January 2011 to December 2012. 
ETHICS COMMITTEE APPROVAL 
Approval from hospital ethics committee was       obtained 
before starting the study. 
CONSENT 
A clearly written informed consent on their own language 
was taken from all patients and from their parents in case juvenile 
PsA 
MATERIALS 
110 consecutive patients attending RCC OPD and 
Rheumatology wards, RGGGH, Madras Medical College, and 
Chennai-3 from January 2011 to December 2012 with clinical 
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features suggestive of psoriatic arthritis during the period of study 
were underwent detailed clinical examination along with family 
history. All the data regarding every patient was recorded in a 
separate proforma made for each patient. All the adult patients 
fulfilling CASPAR classification criteria and children fulfilling 
 ILAR criteria for Juvenile psoriatic arthritis are diagnosed to 
have psoriatic arthritis. 
INCLUSION CRITERIA  
1) Adults who are fulfilling CASPAR classification criteria for 
psoriatic arthritis 
2) Children fulfilling ILAR criteria for Juvenile psoriatic                
arthritis 
EXCLUSION CRITERIA 
1) Reactive arthritis 
2) Rheumatiod arthritis 
3) Enteropathic arthritis 
4) Crystal arthritides 
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METHODS 
Each patient underwent detailed clinical history regarding age 
of onset of joint symptoms, skin manifestations, red eyes, enthiseal 
sites pain, low back pain, neck pain, family history. Detailed 
clinical examination of musculoskeletal system, eyes, nails, skin, 
scalp and other hidden sites for psoriasis were done.  
 Demographic data of all patients were recorded in the 
proforma especially about which system was first involved and 
duration of symptoms. They are categorised into having 
simultaneous onset if the interval between onset the skin and joint 
manifestations are less than three months.The severity of psoriasis 
was assessed and documented based on Psoriasis Activity and 
Severity Index (PASI) score at the baseline.Nails were examined 
for the lesions in the nail bed or nail matrix. For doubtful cases of 
diagnosis of psoriasis, we obtained opinion from our dermatology 
colleagues. 
All the patients underwent detailed ophthalmic evaluation 
especially for present or past evidence of uveitis from Regional 
Institute of Ophthalmology, Chennai. Identical patients were 
classified into defined arthritis type according to Moll and Wright 
based on the predominant musculoskeletal features. 
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All entheseal sites were examined especially the13 sites for    
MASES. Dactylitis was diagnosed based upon the history and 
examination.Conventional X- ray of the hands, feet and other 
region like cervical spine, dorsolumbar and sacroiliac joints 
according to the symptoms at baseline. 
At baseline all the patients underwent haematological, 
biochemical including serum uric acid, and immunological 
investigations. Analyses of RF, CRPand ASO titre were done by 
latex agglutination method in all patients. Anti-CCP antibodies 
were analysed in 82 patients by ELISA method (Genesis lab, anti -
CCP 2 against rat fillagrin antigen). ANA by ELISA method was 
done in 70 patients. 
Analysis for identification of HLA B27 was done in patients 
(28 patients) with axial involvement by microlymphocytotoxicity.  
ANALYSIS 
For assessment of the disease activity the following measures 
were used at baseline, one year and at two years.  
1) Skin : PASI ( at baseline only) 
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2) Peripheral Arthritis : 66 SJC, 68 TJC. 
Patient Global Assessment 
Physician Global Assessment 
3) Enthesitis : MASES 
4) Dactylitis : Present or absent 
5) Spinal disease : BASDAI 
For the follow up and outcome study all the patients are 
categorized into 4 groups according to the time of entry. First group 
(37) of patients were followed and assessed at the end of 1 year and 
2 years. Totally 73 patients were followed and assessed at the end 
of 1 year (1-st, 2-nd and 3-rd group). 
The following are the treatment details for the patients  
1) Methotrexate only   : 92 
2) Methotrexate + Sulphaslazine  : 3 
3) Sulphasalazine only     : 2 
4) Etanercept   + methotrexate   : 4 
5) Etanercept +Cyclosporine  : 1 
6) Inflixamab   + methotrexate  : 1 
7) Intra articular steroids  only  : 2 
8) No DMARD                          : 5 
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STATISTICAL ANALYSIS 
All the data from proforma were transferred to statistical 
analysis using SPSS version 16. Mean for continuous data and 
proportion for discrete data were calculated. Student t test was used 
for comparison of mean values in between groups and chi-square 
test and Fisher‘s exact test were employed to compare the 
proportion between the groups. At a level of 95 % confidence 
interval and p value of less than 0.05 was considered as statistically 
significant. 
 45 
RESULTS 
Totally 110 patients were included for the study over two 
years period. Out of these 61 (55.5 %) were males and 49 (44.5 %) 
were females. 
Table-1: Age distribution 
Age group (years) Frequency Percent 
<16 2 1.8 
16- 20 4 3.6 
21 – 30 20 18.2 
31 – 40 33 30.0 
41 – 50 32 29.1 
51 – 60 14 12.7 
> 60 5 4.5 
Total 110 100.0 
Lowest age of the patient in our study was 9 years and highest 
was 70 years. 
Mean age of the patient was 39.55 years. 
Majority of the patients were in between 3
rd 
to 
5th
decade. 
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Figure-1: Sex distribution 
 
 
Fig-2: First system involved. 
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Fig -3: Duration of Arthritis. 
 
Majority of patients with arthritis presented with the duration of 
less than six months , duration arthritis of more than five years in 9.1 % . 
 Fig 4. Duration of psoriasis.  
 
Duration of skin disease varied from newly diagnosed to 
more than 15 years (5.5%). Majority of patient presented with less 
than 5 years (67.3%). 
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Table-2: Duration of arthritis Vs duration of psoriasis 
Duration of joint 
disease 
Duration of skin disease 
Total 
< 5 yrs 
5 - 10 
yrs 
11 - 
15yrs 
>15 yrs 
< 6 months Count 35 8 2 3 48 
Row % 72.9% 16.7% 4.2% 6.3% 100.0% 
Col % 47.3% 30.8% 50.0% 50.0% 43.6% 
6 months - 
1year 
Count 22 9 0 1 32 
Row % 68.8% 28.1% .0% 3.1% 100.0% 
Col % 29.7% 34.6% .0% 16.7% 29.1% 
 1 - 2yrs Count 3 3 1 0 7 
Row % 42.9% 42.9% 14.3% .0% 100.0% 
Col % 4.1% 11.5% 25.0% .0% 6.4% 
2 - 5 yrs Count 9 3 1 0 13 
Row % 69.2% 23.1% 7.7% .0% 100.0% 
Col % 12.2% 11.5% 25.0% .0% 11.8% 
> 5 yrs Count 5 3 0 2 10 
Row % 50.0% 30.0% .0% 20.0% 100.0% 
Col % 6.8% 11.5% .0% 33.3% 9.1% 
Total Count 74 26 4 6 110 
Row % 67.3% 23.6% 3.6% 5.5% 100.0% 
Col % 100.0% 100.0% 100.0% 100.0% 100.0% 
 
Chi-Square Tests Value P-Value 
Fisher's Exact Test 12.373 0.292 
Majority of patients with arthrtis presented to the hospital 
with in 6 months (43.6 % ) and of them 72.9% of patients had skin 
disease of less than 5 years of duration  and this is not statistically 
not significant. 
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TYPES OF PSORIATIC ARTHRITIS 
Fig-5: Types of arthritis. 
 
The commonest pattern of arthritis observed in our study was 
symmetric polyarthritis in 64 (58.2%) cases. Mixed pattern of 
arthritis were observed in 17.3%. Asymmetric oligoarthritis 
constituted about 17 (15.5% ) patients. Predominant  axial disease 
was observed in 9 (8.2%) patients and predominant DIP arthritis 
0.9% of cases.Arthritis mutilans was observed in one patient in the 
mixed type. 
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TYPES OF PSORIASIS 
In our study the commonest type of psoriasis observed was 
psoriasis vulgaris in 71 (64.5%) patients. Isolated scalp lesions 
were observed in 18 (16.4%) of patients.Erythrodermic  and guttate 
varieties constituted about 0.9 % each.Isolated  nail involvement 
with family histoty of psoriasis occurred in 4 (3.6% ) cases.Nail 
lesions were seen along with other types of psoriasis occurred in 
more number of ceses. 
Fig-6: Types of psoriasis. 
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SEVERITY OF SKIN DISEASE AT BASELINE:  
Actitivity of skin disease was assessed for 106 patients at the 
time of entry to correlate with the joint disease. Four patients had 
only nail lesions suggestive of psoriasis with family history of 
psoriasis. 
Majority of patients with psoriasis had PASI score of less 
than 5 (64 patients-60.4. %).Two patients (1.9 %) had severe skin 
disease i.e PASI more than 30. 
Table-3: Severity of skin disease at baseline 
PASI Base line Frequency Valid Percent 
<5 64 60.4 
5-10 24 22.6 
11-20 13 12.3 
21 – 30 3 2.8 
> 30 2 1.9 
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Table-4: Comparison of skin score among the various types of arthriti s  
Joint Type 
PASI Base line 
Total 
<5 5-10 11-20 21 - 30 > 30 
Sym Poly Count 39 16 7 1 1 64 
Row % 60.9% 25.0% 10.9% 1.6% 1.6% 100.0% 
Col % 60.9% 66.7% 53.8% 33.3% 50.0% 60.4% 
Asym Oligo Count 8 5 3 0 0 16 
Row % 50.0% 31.3% 18.8% .0% .0% 100.0% 
Col % 12.5% 20.8% 23.1% .0% .0% 15.1% 
SPA Count 7 0 1 0 0 8 
Row % 87.5% .0% 12.5% .0% .0% 100.0% 
Col % 10.9% .0% 7.7% .0% .0% 7.5% 
Mixed Count 10 2 2 2 1 17 
Row % 58.8% 11.8% 11.8% 11.8% 5.9% 100.0% 
Col % 15.6% 8.3% 15.4% 66.7% 50.0% 16.0% 
DIP Count 0 1 0 0 0 1 
Row % .0% 100.0% .0% .0% .0% 100.0% 
Col % .0% 4.2% .0% .0% .0% .9% 
Total Count 64 24 13 3 2 106 
Row % 60.4% 22.6% 12.3% 2.8% 1.9% 100.0% 
Col % 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
 
Chi-Square Tests Value P-Value 
Fisher's Exact Test 16.476 0.420 
Majority of symmetric polyarthritis patients (60.9 % )had 
skin score of less than 5 and other subtypes of arthritis also had less 
severe skin disease activity. 
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Table-5: Comparison of skin type vs arthritis type 
Skin Type  
Joint Type 
Total Sym 
Poly 
Asym 
Oligo 
SPA Mixed DIP 
PSV Count 42 13 2 13 1 71 
Row % 59.2% 18.3% 2.8% 18.3% 1.4% 100.0% 
Col % 65.6% 76.5% 22.2% 68.4% 100.0% 64.5% 
Scalp Count 11 1 4 2 0 18 
Row % 61.1% 5.6% 22.2% 11.1% .0% 100.0% 
Col % 17.2% 5.9% 44.4% 10.5% .0% 16.4% 
PSV + Scalp Count 3 0 0 0 0 3 
Row % 100.0% .0% .0% .0% .0% 100.0% 
Col % 4.7% .0% .0% .0% .0% 2.7% 
Nails Count 0 1 1 2 0 4 
Row % .0% 25.0% 25.0% 50.0% .0% 100.0% 
Col % .0% 5.9% 11.1% 10.5% .0% 3.6% 
Plantar Count 0 0 1 1 0 2 
Row % .0% .0% 50.0% 50.0% .0% 100.0% 
Col % .0% .0% 11.1% 5.3% .0% 1.8% 
Palm plantar Count 5 2 1 0 0 8 
Row % 62.5% 25.0% 12.5% .0% .0% 100.0% 
Col % 7.8% 11.8% 11.1% .0% .0% 7.3% 
Scalp + Nails Count 2 0 0 0 0 2 
Row % 100.0% .0% .0% .0% .0% 100.0% 
Col % 3.1% .0% .0% .0% .0% 1.8% 
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Skin Type  
Joint Type 
Total Sym 
Poly 
Asym 
Oligo 
SPA Mixed DIP 
Erythrodermic Count 1 0 0 0 0 1 
Row % 100.0% .0% .0% .0% .0% 100.0% 
Col % 1.6% .0% .0% .0% .0% .9% 
Guttate Count 0 0 0 1 0 1 
Row % .0% .0% .0% 100.0% .0% 100.0% 
Col % .0% .0% .0% 5.3% .0% .9% 
Total Count 64 17 9 19 1 110 
Row % 58.2% 15.5% 8.2% 17.3% .9% 100.0% 
Col % 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
 
Chi-Square Tests Value P-Value 
Fisher's Exact Test 48.627 0.051 
Although psoriasis vulgaris is the commonest type in 
symmetric polyarthritis (65.6%)and scalp psoriasis in SPA 
(44.4%),this not statistically significant.(p0.051).  
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Table-6: Radiographic abnormalities at entry 
Change Frequency Percentage 
Soft tissue swelling 28 25.5 
Joint space narrowing 17 15.4 
Sacroiliitis 24 21.8 
Erosions 5 4.5 
C-spine abnormalities 7 6.4 
Periosteal reaction 2 1.8 
Osteopenia 1 0.9 
Table-7: Extra-articular features 
 Frequency Percentage 
Anterior uveitis 4/110 3.6 
Hyperuricemia 5/110 4.5 
ANA positivity 10/70 14.2 
Raised ASO titer 9/110 8.1 
RF positivity 7/110 6.3 
Anti-CCP positivity 8/82 9.7 
HLA B 27 5 /28 17.8 
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Table-8: Correlation between skin and enthesitis index 
  MASES_Base line 
PASI_Base line Correlation 0.585 
P-Value 0.000 
N 106 
There was strong statistically significant correlation was 
observed between skin disease activity and enthesitis indices. 
Fig-7 : Mean ESR at Baseline 
 
Mean ESR value  of patients with mixed type is 50.74 
(highest)and in asymmetric oligoarthritis  is 30.41. 
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Table09: Correlation of skin disease activity with joint disease 
activity:[ at enyry ] 
  
PASI 
Base line 
66 SJC Base line Correlation 0.046 
P-Value 0.639 
N 106 
68 TJCBase line Correlation 0.091 
P-Value 0.355 
N 106 
ESR Base line Correlation 0.198 
P-Value 0.042 
N 106 
[PASI was not calculated in 4 patients with isolated nail 
disease] 
There was a positive correlation (0.091) observed between 
tender joint count and PASI at entry but this was not statistically 
significant. Statistically significant correlation (p=0.042) was 
noticed between baseline ESR and PASI. 
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Table-10: Outcome at 1 Year 
Outcome at 1 year Frequency Valid Percent 
Mean ESR at 
Baseline 
PsARC 42 57.5 49.62 
Persist 14 19.2 46.71 
Flare 2 2.7 53.50 
Poly 3 4.1 41.67 
Lost to Follow up 12 16.4 46.33 
Total 73 100.0 48.30 
 During follow up and assessment at one year, out of 73 
patients 42 (57.5%) attained PsARC response,14 cases (19.2% ) 
showed persistent disease activity, flare in 2 (2.7%)cases and 
progression to polyarthritis in 3 (4.1%).12 patients (16.4%) lost the 
follow up. Mean baseline ESR in patients who had PsARC response 
is lower than who had flare . 
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Table-11: Outcome at 2  years : 
Outcome at 2 years Frequency Percent 
Mean ESR at 
baseline 
PsARC 18 48.6 45.22 
Persist 5 13.5 59.60 
Flare 3 8.1 55.00 
Poly 2 5.4 46.50 
Lost to Followup 8 21.6 45.50 
MDA 1 2.7 8.00 
Total 37 100.0 47.08 
Totally 37 patients were enrolled for follow-up for 2 years, 29 
cases were assessed at the end of two years (8 patients lost to 
follow-up). 18 patients showed PsARC response and one patient 
attained Minimal Disease Activity response and persistent disease 
activity in 5 cases (13.5%). 
When comparing the baseline ESR among those groups, it 
was lower in PsARC and MDA positivity than in patients with flare 
or persistent disease activity. 
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Table-12: Analysis at the end of two years : 
 
ACTIVITY 
AT THE 
END 
N Mean 
Std. 
Deviation 
P-Value 
66 SJC_Base 
line 
PsARC +ve 18 10.72 3.675 0.098 
PsARC -ve 10 8.09 4.527 
68 TJC_Base 
line 
PsARC +ve 18 13.22 4.305 0.090 
PsARC -ve 10 10.00 5.495 
ESR_Base 
line 
PsARC +ve 18 45.22 22.254 0.471 
PsARC -ve 10 53.70 20.519 
At the end of follow up period of two years, when comparing 
the patients who showed positive PsARC  with negative PsARC  
the baseline ESR in the positive group (45.22 vs. 53.70) was lower 
although it is statistically not significant(p=0.471). 
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Table-13: Comparision of anti-CCP(ACPA) positive vs negative: 
 Patient group N Mean Std. Deviation P-Value 
66 SJC 
Base line 
ACPA +ve 8 12.13 4.291 0.005 
ACPA -ve 74 7.38 4.558 
68 TJC 
Base line 
ACPA +ve 8 14.00 4.986 0.025 
ACPA -ve 74 9.46 5.473 
ESR Base line ACPA +ve 8 60.50 21.527 0.076 
ACPA -ve 74 45.14 23.449 
Anti-CCP antibodies by ELISA method was done in 82 
patients,out of which it was positive in 8 cases(9.7%).  When 
comparing these two groups, actively inflamed joint count 
(significant p=<0.05) and ESR at baseline were higher among anti -
CCP positive patients. 
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Table-14: Imaging Abnormalities  
 
Patient group 
Total 
ACPA +ve ACPA -ve 
N % N % N % 
Imaging Normal 0 .0 47 100.0 47 100.0 
Abnormal 8 22.9% 27 77% 35 100.0 
Total 8 9.7% 74 90.3% 82 100.0 
 
Chi-Square Tests (Fisher's Exact Test) Value P-Value 
Imaging * Antibodies - 0.010 
When comparing the imaging abnormalities, all patients with 
anti-CCP positivity had radiological damage which was statistically 
significant (p=0.01). 
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DISCUSSION 
In our study of 110 patients, majority of them in the age 
group of 3rd to 5th decade constituted around 70%.  Lowest age  
was 9 years and highest age was 70 years.  The mean age of the 
patient with psoriatic arthritis was 39.55 years. 
Observations 
Our 
study(110) 
Rajendran 
CP et   al
9
 
2003 
(116) 
Shah et 
al
77
1995 
(102) 
Pranesh 
et 
al
78
1998 
(12) 
Mean age (yrs) 39.55 40.9 38.17 40 
Sex ratio 1.2:1 2:1 1.8:1 1:2 
Arthritis 
precede skin 
disease (%) 
24.5 12.1 
 
5.8 8.3 
Arthritis after 
skin (%) 
56.4 50.8 63.8 50 
Simultaneous 
onset 
19.1 37.1 19.7 41.7 
Out of 110 cases ,slight male preponderance of 1.2: 1  was 
observed and the similar finding was observed by Rajendran CP et 
al and showed male to female ratio of 2: 1.  But other 
epidemiological study by Gladmann et al and Kammer et al showed 
equal sex incidence.
35,79
 Female preponderance in psoriatic arthritis 
was reported by Pranesh et al.
78 
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Skin disease preceding arthritis was seen in 56.4% like other 
studies by Rajendran CP et al and Shah et al.  Arthritis preceded the 
psoriasis in 24.5% of cases and simultaneous onset (within 3 
months of onset of each other) was noted in 19.1% of 
patients.Majority of patients with arthritis presented to the hospital 
within 6 months of disease onset (43.4%), among these cases 72.9% 
of patients had the skin disease duration of less than 5 years.  
Majority of patients in all types of psoriatic arthritis had the 
skin disease duration of less than 5 years (67.3%).  Our study had 
shown that the prevalence of arthritis in patients with psoriasis 
duration of more than 10 years is low (9.1%).  This was also shown 
by Prasad et al previously.
7
 Occurrence of Arthritis in patients with 
long standing skin disease is less common. 
Family history of Psoriasis was found in 6% of cases but it 
was observed in 27.5% of patients in the previous study.
7
 Based 
upon recent genetic studies among the Psoriasis patients certain 
MHC Antigens like B17, B18, B27 and DR7 were seen more 
commonly in patients with Arthritis than in patients without 
Arthritis. 
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As previously reported by Rajendran CP et al and Neeraja 
Puri et al ,our study also found that  psoriasis vulgaris was the 
commonest skin type among the patients with arthritis (64.5%).
80
 
Isolated nail disease with family history of psoriasis and the 
arthritis typical psoriatic arthritis were observed in 3.6% of cases. 
Guttate type and erythrodermic types  of psoriasis were seen 1 
patient each. Comparing the skin type with the arthritis type 
although psoriasis vulgaris is the commonest skin lesion in patients 
with symmetric polyarthritis (65.6%) and scalp psoriasis in 
spondyloarthritis (44.4%) , but this is not statistically significant.  
Like  other previous studies (Rajendran CP et al, Gladmann et 
al, Singh et al) our study also showed  symmetric   polyarthritis  as 
the commonest pattern of joint disease. Predominent  DIP Arthritis 
was observed only in 1 patient(0.9%), but we observed DIP 
Arthritis in more number of cases along with other sub types.  
Second major subtype in our study was mixed pattern (axial + 
peripheral arthritis) in 17.3% of cases.   Predominent axial disease 
was observed in 8.2% of cases.   Another study by Amer Ijaz from 
Pakistan showed that oligoarthritis as the predominent type .
81 
The commonest imaging abnormality in our study patients 
were soft tissue swelling around the joints in 25.5% of cases.  Joint 
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space narrowing were seen in 15.4% of cases, but the study by 
Prasad et al  observed joint space narrowing  as the most common 
radiological change  62.5% of patients.  We found periosteal new 
bone formation in 1.8% of cases and sacroilitis in 21.8% of cases, 
among them majority had bilateral asymmetric involvement. It was 
observed the presence of more than one imaging abnormality in few 
cases especially in mixed types in our study. We have not analyzed 
the correlation between the type, severity of imaging abnormality 
and the duration of the arthritis. This is one of the pitfalls in our 
study. 
According to Brower et al, marginal erosions and joint space 
narrowing are initial lesions while periosteal new bone formation, 
osteolysis and ankylosis are seen in advanced stage of disease.
82 
Hyperuricemia was observed in 4.5% of cases, but Lambert 
and Wright et al found high prevalence of uric acid values above 
the normal range and this may be due to high cell turnover and 
increased  purine metabolism .
7 
Raised ASO titre was observed in 8.1% of cases when 
compared to previous author (12.7%) and this signifies the 
antecedent or current streptococcal infection.
9 
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Anterior uveitis  was present in 3.6% of cases; among them 2 
patients were HLA B27 antigen positive. 
Findings (%) Rajendran CP et al
9 
Our study 
Hypruricemia 1.7 4.5 
Raised ASO titre 12.7 8.1 
Anterior uveitis 1.7 3.6 
RF positivity 3.4 6.3 
ANA positivity 5.4 14.2 
Anti-CCP positivity - 9.7 
Dactylitis 19 21 
HLA B 27 - 17.8 
In our study, majority of patients with arthritis had low skin 
disease activity as evidenced by low PASI Score but another study 
by Prasad et al showed major proportion of patients had moderate 
to severe skin disease activity (PASI 10 - 30). 
In our study, majority of patients with symmetric polyarthritis 
had skin score of PASI less than 5 (60.9% of symmetric 
polyarthritis).  This is in contrast to the report by previous author 
showed the majority of patients with arthritis had moderate skin 
disease activity.
7
 We did not find a significant relationship between 
arthritis sub types and pattern of skin disease like previous 
studies.
9,83 
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Our study showed that baseline mean ESR was more than 
normal in all patterns of arthritis and highest value observed in 
mixed type (50.74) and in asymmetric oligoarthritis the mean ESR 
was 30.41. 
Analyzing the correlation between skin disease activity and 
joint disease activity in our study, there was  positive correlation 
between PASI Score and swollen as well as tender joint count 
although it was not statistically significant.  But we found a 
statistically significant (p 0.042) positive correlation (0.198) 
between PASI and mean ESR value at baseline.   This positive 
correlation was supported by various studies.   
Elkayam et al showed a significant correlation between PASI 
score and joint count and Schober‘s test and cervical spine 
involvement.
84
  In that study they observed simultaneous flare of 
skin and joint disease more in the proportion of patients who had 
the onset of  psoriasis and joint disease within 1 year.  But they did 
not find association among the group of patients who had separate 
onset of joint and skin disease.  But few other studies showed no 
association between skin and joint diseases.  A prospective study by 
Jones SM et al among 100 patients with psoriatic arthritis, skin and 
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nail disease activity did not correlate with the joint severity, joint 
activity or functional status.
85 
Another study by Amer Ejaz suggests no association between 
skin disease severity and the development of arthritis.
81 
There was very strong positive correlation between enthesitis 
score and disease activity score (correlation coefficient 0.585 and p 
value 0.000). 
Anti - CCP antibodies were positive in 9.7% of cases (8 out 
of 82 patients) .When comparing the anti-CCP positive and 
negative groups in patients with psoriatic arthritis mean tender and 
swollen joint count were higher in patients with anti-CCP positivity 
which is statistically significant .Radiographic abnormalities were 
significantly more in patients with Anti-CCP positivity (p 0.010). 
  Inanc N et al found Anti-CCP 2 was positive in 12.5% of 
patients with psoriatic arthritis and that was associated with 
symmetrical polyarthritis.
86
  In our study all anti-CCP positive 
patients had features typical of psoriatic arthritis and none of them 
had features suggestive of RA like juxta articular osteoporosis or 
nodules.  In a prospective analytical study by Korendowych E et al 
with the aim of determining prevalence and association of anti -CCP 
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antibodies in psoriatic arthritis, they observed anti -CCP positivity 
in 5.6% of cases and concluded that anti-CCP antibody positivity 
was associated with higher number of swollen joints and HLA DR 
B1 shared epitope, more erosive disease and requiring early 
DMARD therapy.
87
  In that study RF was positive in 8.7% of cases 
and they did not find an association with clinical, imaging or 
genetic correlation. 
Another study by Nermeen et al they demonstrated Anti-CCP 
positivity in 17.5% of cases in association with high number of 
involved joints and erosions as well as functional impairment.
49 
Out of 70 patients analysed ,ANA  was positive in 14.2% . 
According to Lambert , ANA positivity was reported in 7 to 77 % 
of patients with psoriatic arthritis and these antibodies were thought 
to react with stratum corneum antigens.
88
  Other immunological 
abnormalities in psoriatic arthritis include anticytokeratin18 and 
antiepidermal keratin antibodies.
89 
A prospective study by Johnson et al  at Toronto Psoriatic 
Arthritis Clinic showed ANA positivity in 47% of cases and in 14% 
patients showed significant titre of more than 1 : 80 .
50
  In view of 
association of auto antibodies development with anti TNF drugs 
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baseline ANA scenning may be useful  in patients with psoriatic 
arthritis for future reference. 
At the end of 1 year, 57.5% of  patients attained PsARC 
response and progression from oligoarthritis to poly arthritis was 
noted in 4.1% of cases.  12 patients lost to follow up.  When 
comparing the baseline ESR in patients who attained PsARC and 
flare, there was the high baseline ESR value in patients with flare.  
From group 1 of study population   37 patients were enrolled 
for 2 years follow up and at the end of 2 years 18 patients (48.7%) 
have shown PsARC response and Minimal Disease Activity was 
noticed in 1 patient. 
Persistent disease activity, flare up of symptoms, progression 
to polyarthritis were noted in 13.5%, 8.1%, 5% of patients 
respectively.  7 patients lost to follow up. 
Comparing the group of patients who have shown 
improvement response to non-improvement group, mean baseline 
ESR was higher in nonimprovement group although statistically not 
significant. One of the limitations of our study is that assessment 
the radiologic progression was not studied. 
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One of the prospective outcome studies in early  psoriatic 
arthritis by Kane D et al ,they had followed up 129 patients for 2 
years and at the end of 1 year period 26% of patients were in 
remission and at 2 years 21% in remission.  Also they observed low 
rate of DMARD free remission in 11% of patients at 2 years.
72 
Absence of actively inflammed joints for a period of 12 
months is called as ‗remission‘ and according to Gladmann et al  
after a period of follow up of 2.6 years only 6% of patients showed 
prolonged remission and 52% of cases had flare .
90
Among our 
patients 1 out of 37 patients at the end of 2 years follow up showed 
Minimal Disease Activity   but we did not find remission in any 
patient.  
 In another follow up study Gladmann DD et al found that 
during follow up of patients with psoriatic arthritis, for each joint 
inflammation there was 4% increased risk of damage at the next 
visit at 6 months later.
91
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CONCLUSION 
1) The mean age of the patients in our study was 39.5 years. 
2) Slight male preponderance was observed (1.2:1 ). 
3) Skin disease preceding arthritis was noted in majority of 
patients (56%)and simultaneous onset was found in 19 % of 
patients. 
4) Onset of arthritis after 10 years of psoriasis is 
uncommon(9%). 
5) Psoriasis vulgaris was the commonest skin pattern and 
symmetric polyarthritis was the commonest subtype of 
arthritis  noted in our study. 
6) The prevalence of ANA, anti-CCP and RF positivity in our 
patients  were 14.2%,  9.7 %,6.3% respectively. 
7) Anterior uveitis was observed in3.6 % of our patients. 
8) Positive correlation between skin and joint disease activity 
was noticed although statistically not significant.  
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9) Anti-CCP positive psoriatic arthritis patients had higher 
number swollen, tender joints and more radiographic damage. 
10) At the end of one year follow-up, 57.5% of patients showed  
PsARC improvement response. 
11) At the end of two years follow-up, 48.7% of patients showed 
PsARC response  and 2.7% showed Minimal Disease Activity 
response. 
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RIGHT THUMB INTERPHALENGEAL JOINT ARTHRITIS 
 
PSORIASIS WITH DEFORMING ARTHRITIS 
 
 100 
 
BILATERAL SACROILIITIS 
 
RIGHT 4
TH
 PROXIMAL PHALANX PERIOSTEAL 
REACTION 
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NAIL PITS SECONDARY ANKYLOSING SPONDYLITIS 
  
A STUDY ON CLINICO- IMMUNOLOGICAL PROFILE 
AND TREATMENT OUCOME OF PSORIATIC 
ARTHRITIS 
Name:            Age:       Sex:      Occupation: 
Address: 
 
D.O.E.   RCC No.                       mobile: 
Complaints : 
 
H/o. Present illness: 
 
 
 
 
H/o. Past Illness: 
 
DM-           HTN-   DYSLIPID-   BA-             PT- 
        
Personal History: 
 
Treatment History: 
 
Family History: 
 
General Examination : 
Height:   Weight:    BMI: 
Pallor:   Icterus    Lymphadenopathy: 
A STUDY ON CLINICO- IMMUNOLOGICAL PROFILE 
AND TREATMENT OUCOME OF PSORIATIC 
ARTHRITIS 
 
Pedal Edema:  Clubbing:                 
Skin: 
PASI: 
Nails: 
 
Hair: 
Vital Signs    :       PR      BP 
Cardiovascular System: 
Respiratory System: 
Abdomen: 
Central Nervous System: 
Musculo Skeletal System Examination: 
 
 
 
 
 
Enthesitis:                                                                   Dactylitis: 
MASES: 
66SJC:          68TJC:     BASDAI: 
PGA:      PtGA: 
INVESTIGATIONS : 
Haemogram ; 
Hb:   TC:    DC: 
PLT:   RBC:    PCV 
ESR:    
Immunological : 
ASO:   RF:    CRP: 
Anti CCP:                          HLA B27:       ANA : 
 
Bio-Chemistry : 
Sugar:                 Urea:            Creatinine: 
Uric Acid:  Bilirubin:            SGOT: 
SGPT:                 ALP:            Total Proteins:               Albumin:  
Total CHO:  LDL:           HDL:         TGL: 
Radiography: 
 
 
 
REFERRALS : 
Dermatology:     Ophtholmogy: 
 
 
Cardiology:     Others : 
 
 
 
 
FINAL DIAGNOSIS : 
 
TREATMENT :                    Intra-articular:  
S.No Name Age RCC Sex Joint Duration Skin Duration FIRST SYSTEM Family History Comorbid Skin Type Joint Type Imaging Antibodies
1 Jeyasimman 54 53991 M 1 month 3 yrs SKIN -- HT,DM 3yrs PSV Asym oligo STS ASO
2 DEVIKA 31 54067 F 3YRS 3YRS SIMULTANEOUS -- - PSV +SCALP SYM POLY N -
3 ALPHONSA 34 54064 F 1 MONTH NEW SIMULT - - SCALP SYM POLY N ANA
4 VICTOR 32 54203 M 6MONTHS NEW JOINT - - SCALP ASYM OLIGO - -
5 RAJA 33 54225 M NEW NEW SIMULT - - SCLP SYM POLY STS -
6 JOTHY 48 54301 F NEW 1 YR SKIN - - PSV SYM POL STS -
7 SARAVANAN 27 54311 M 7months NEW JOINT father PSA - NAIL SPA UNI SI -GR2 -
8 SARGUNAM 49 54367 F 4years NEW JOINT - - PSV SYM POLY n -
9 BRASS 65 54538 F 10years 20 yrs SKIN - HT Ps.V ASYM OLIG - RF
10 KAVITHA 27 53308 F 2months 1 year SKIN - PALMO-PLANT ASYM OLIG STS -
11 MARIASUSAI 32 53305 F 3months 1.5 yrs SKIN - - PSV SYM POL - -
12 SHAJITHA BANU 28 53307 F 7months 7years SKIN - obese PSV+SCALP SYM POL STS ACPA
13 SHAKIRA BEE 34 53188 F 9months 7YEARS SKI N - - PsV SYM POL - -
14 CHANDRA 59 53429 F 6months NEW JOINT - - PALMO-PLANT SYM POLY+DIP - -
15 DHANALAKSHMI 47 54063 F 6months NEW JOINT - SCALP SYM POL - STS
16 MOORTHY 45 53718 M 3months 6months SIMULT - DM SCALP SYM POLY EROSION MCP -
17 RAJENRAN 45 53695 m 2months 10yrs SKIN - - PsV SYM POL STS ACPA
18 KAMSALA 40 53663 F 2months 1YEAR SKIN - - PsV DIP - -
19 SANTHANAKRISHN 70 53617 M 1year 1YEAR SIMULT - DM SCALP+NAIL SYM POL osteopenia RF
20 SANKARAN 44 53607 M 1 MONTH 15YEARS SKIN - - PsV SYM POL EROSIONS ACPA
21 USHA 33 53580 F 6months NEW JOINT - - PsV SYM POL - -
22 SUMATHY 26 53558 F 3years 6MONTHS JOINT - HYPOTHY PsV SYM POL - -
23 SURESH 20 53530 M 10months 10YEARS SKIN - - PalmoPlantar SYMPOLY STS-knees -
24 SIVANANTHAN 50 53479 M 1 month 5YEARS SKIN - - PsV SYM POLY - -
25 GOVINDAN 41 53477 M 1month 19YEARS SKIN - kidn don ERYTHRODERMIC SYM POL STS UA-7.8,ASO
26 PERUMAL 45 53431 M 6months NEW JOINT - - SCLP,NAIL SYM POL STS -
27 MURALI 43 53011 M 1year 7YEARS SKIN - - PsV POL+SPA GR 2 SI ANA
28 LOGANATHAN 61 53009 M 4years 4YEARS SIMULT - - PsV ASYM OLIG STS -
29 VEERAKUMAR 47 53081 M 10years 10YEARS SIMUL - HTN.CAD PsV SYM POL JSN hand JOINTS -
30 SARALA 42 54230 F 1year 10YEARS SKIN - HTN PsV SYM POL STS RF
31 VIJAYALAKSHMI 26 54053 F 1.5months NEW SIMULT - - PalmoPlantar SYM POL STS ACPA
32 DEVARAJ 31 53951 M 5years NEW JOINT - - SCALP SPA+HIPS hipjsn,SI B\L B27
33 VADIVEL 37 53937 M 2weeks NEW SIMULT - - SCALP POLY-DIP STS -
34 LAKSHMI 43 53805 F 2months NEW SIMULT - father ps NAILS MIXED STS,B|L SI ANA
35 MADHU 50 53301 F 1month 2YEARA SKIN - - SCALP SYM POL STS -
36 DEVARAJ 54 53210 M 1.5months 1YEAR SKIN - - PsV SYM POL - RF
37 A.A.PRABU 26 53263 M 1 year 5YEARS SKIN - - PsV SPA Gr3 SI B\L,HIPS ASO
38 CHINNATHAMBI 55 53768 M 1week 2 years SKIN - - PsV SYM POL - -
39 RICHARD 35 54163 M 25years 7YEARS JOINT - - PSV MIXED Grd 4 SI B/L UA-9,ASO
40 MANIKANDAN 22 53406 M 3years 1.5YEARS JOINT - - PalmoPlantat SYM POL STS -
41 SUNDARAM 47 53993 M 2weeks 6YEARS SKIN - Ret.Pig PsV ASY.OLIG STS ANA
42 VALLI 35 54339 F 5years 10YEARS SKIN motherPsA - PsV SYM POL periost react -
43 SELVI 31 54607 F 3months NEW SIMULT - - SCALP SYM POL STS -
44 RAJA 40 54659 M 4months NEW JOINT - HTN Plantar SPA Grde 3 B/L B27
45 MEENAKSHI 56 54665 M 6months NEW JOINT - - PsV ASYM OLIG - -
S.No Name Age RCC Sex Joint Duration Skin Duration FIRST SYSTEM Family History Comorbid Skin Type Joint Type Imaging Antibodies
46 suresh 41 51677 M 8months 2YEARS SKIN - LDL SCLP SYM POL STS -
47 KANNIAPPAN 50 54679 M 1year 30YEARS SKIN fatherPS - NAILS MIXED Grd 2SI B/L -
48 VIJAYA 27 54842 F 2months NEW SIMULT - - PSV SCLP SYM POL STS -
49 ADHIKESAVAN 17 54862 M 3years 6YEARS SKIN - - PsV JUV PSA - -
50 VENI 31 54882 F 1month NEW SIMUL - - SCLP ASYM OLIG - ANA
51 RAMAMOORTHY 42 54925 M 5years 8YEARS SKIN - HTN PsV SYM POL - -
52 CHITRA 26 54907 F 3months NEW SIMULT - - PsV SYM POL - -
53 MdHussain 53 54930 M 6yrs 20YEARS SKIN - - PsV MIXED MUTILANS UA-7.7
54 KOTHANDAN 37 54478 M 1month 1YEAR SKIN - - PsV ASYM OLIG - -
S SULOCHANA 45 54522 F 1month 3YEARS SKIN - HTN PalmoPLantar SYM POL STS RF
56 VALARMATHY 51 54590 F 2years NEW JOINT - HTN PsV SYM POL - -
57 UMAMAHESWARI 40 54602 F 2years 10YEARS SKIN - HYPOTHY PsV SYM POL - -
58 VELMURUGAN 40 55003 M 6years 2MONTHS JOINT - UVEITIS PsV MIXED GR4 B/L B27
59 SHANMUGAM 34 54672 M 6months 8YEARS SKIN - - PsV SYM POL GR 2 SI -
60 BHAVANI 30 54400 F 3months 2YEARS SKIN - OBESE PsV ASYM OLIG - ANA
61 SHAKILA 45 54829 F 2months 10YEARS SKIN - - PsV SYM POL - -
62 BASKAR 29 54530 M 3months 2YEARS SKIN - - PsV SYM POL HIP JSN AS0
63 RABECCAL 54 54595 F 1year 6YEARS SKIN - - PsV SYM POL - -
64 SIVAGNANAM 69 54237 M 1month NEW SIMULT - postCABG PsV SYM POL HIP JSN RF
65 SRINIVASAN 48 54780 M 1month 2 YEARS SKIN - - PsV SYM POL - ANA
66 RABECCA 21 54487 F 2MONTHS NEW SIMULT - - PALMO-PLANT ASYM OLIGO - -
67 SURESHBABU 41 54677 M 7YEARS NEW JOINT - HTN SCALP SPA GRDE 2 B/L B27
68 VIJAYA 47 55163 F 3months 10YEARS skin - RtUVEITIS PsV SYM POL - -
69 LATHA 35 55217 F 3years 3YEARS SIMULT daugh PSA LtUVEITIS PsV MIXED Gr2 SI -
70 GEETHA 38 55091 F 3years 5YEARS SKIN - - PsV SYM POL STS ANA
71 RUPAVATHY 34 55090 F 4months 69MONTHS SKIN - - SCLP SYM POL JSN ACPA
72 REGINAMARY 31 55089 F 2months NEW SIMULT - - PSV ASYM OLIGO - -
73 PANJAVARNAM 62 55055 F 2years NEW JOINT - - SCLP SYM POL STS -
74 sudha 29 55270 F 2MONTHS 3YEARS SKIN - - PsV MIXED 3GRDE SI -
75 RAMESHKUMAR 37 55273 M 3years NEW JOINT - - SCLP SPA N -
76 FATHIMABANU 55 55335 F 8years NEW JOINT mother ps HTN,uveit NAILS ASYM OLIG - -
77 NEJMA 37 55349 F 1year 2.5YEARS SKIN - - PsV SYM POL - -
78 SHERIF 27 55407 M 6months 1.5years SKIN - - PsV SYM POL - -
79 PONNI 51 55425 F 5months 20YEARS SKIN - - PsV SYM POL - ANA
80 SEKAR 40 55504 M 5months 2YEARS SKIN - - PsV SYM POL - -
81 BAKTHAVATCHALA 48 55234 M 6months 1YEAR SKIN - - PsV SYM POL JSN ACPA
82 MANONMANI 46 55208 F 3months 25YEARS SKIN - - PsV ASYM OLIG -
83 SIVANANDAN 55 55O99 M 2years 10YEARS SKIN - - PsV SYM POL EROSIONS ACPA
84 UMA 40 55362 F 3months 15YEARS SKIN - - PsV SYM POL - -
85 PRADEEPKUMAR 28 55129 M 6MONTHS 10YEARS SKIN - - PsV SPA B/L GR2 -
86 ANREWS 34 55073 m 21yrs NEW JOINT motherPs CATARAC PsV SPA-JAS B/L GR3,hip ASO
87 ARUMUGAM 49 54084 M 1year 4YEARS SKIN - - PsV SYM POL STS,EROSIONS RF
88 SAROJA 51 55424 F 3YEARS 14YEARS SKIN - - PsV SYM POL PERI REACT -
89 RAJKUMAR 35 55219 M 4months 7YEARS SKIN - - PsV ASYM OLIG - -
90 JAIGANESH 26 55245 M 2years 13YEARS SKIN - DM,oldPT PsV MIXED GRD 4 SI b/l -
S.No Name Age RCC Sex Joint Duration Skin Duration FIRST SYSTEM Family History Comorbid Skin Type Joint Type Imaging Antibodies
91 VALLARASU 9 55187 M 1year 3MONTHS JOINT - - GUTTATE JUV  PSA STS ASO
92 PARIMALA 47 55324 F 1year 1YEAR SIMULT sis PS - PsV SYM POL JSN ACPA
93 SHANMUGAM 49 55625 M 8months 1.5YEARS SKIN - - PsV ASYM OLIG - -
94 RAJU 38 55605 M 4months 8YEARS SKIN PLHA-6yrs PsV ASYM OLIG PERIOST -
95 AMUTHA 30 55517 F 6months NEW JOINT - - PsV ASYM OLIG - -
96 anniah 52 55702 M 4months 10YEARS SKIN - - PsV SYM POL - -
97 SIVAN 45 55638 M 2months 2YEARS SKIN - - PsV SYM POL ASO
98 DEVI 31 55609 F 3MONTHS 1YEAR SKIN - - PSV SYM POL - ANA
99 SETTU 47 55670 M 1year NEW JOINT - - SCALP SYM POL - -
100 SUNDARAM 49 55822 M 1year 9YEARS SKIN - - PsV SYM POL EROSIONS
101 TAMILARASAN 19 55895 M 1year NEW JOINT - - PsV MIXED GRDE 2B/L ASO
102 ELANGOVAN 60 55927 M 6years 8YEARS SKIN - - SCALP SPA GRDE 4B/L -
103 BALAKRISHNAN 20 51541 M 17years NEW JOINT - CRF,U.A,STONE PLANTAR JUV SPA GRDE 2 SI B/L UA-8
104 venkatesan 37 55950 m 1year NEW JOINT - - Pal+Plantar spa GRDE3SI B/L -
105 MASTHAN 42 56049 M 2months new SIMULT B27 + scalp spa grde3 si B27
106 SHANTHI 40 56070 F 1YEAR 3YEARS SKIN - - PSV SYM POL - -
107 AKSARA 13 55912 F 3MONTHS 3MONTHS SIMULT - - PSV JUV PSA - -
108 AMSALEKHA 21 55798 F 3MONTHS 2YEARS SKIN - - PSV ASYM OLIG - -
109 SATHYARAJ 28 56040 M 2YEARS 5MONTHS JOINT - - PSV MIXED GRDE2B/L+JSN UA-9
110 TONY 28 56081 M 2YEARS 9YEARS SKIN - - PSA SYM POL EROSIONS -
DMARD 66 SJC68 TJC PGA PtGA ESR CRP Dacty MASES BASDAI PASI 66 SJC 68 TJC PGA PtGA ESR CRP Dacty
MTx 15mg 3 4 4 4 19MM + Rt 3,4,5 fingers - 9.3 - 2 1 2 25 + 1
MTX 15MG 16 20 4 5 45mm + - 2 4.6 3 6 2 2 13 + -
MTX15MG 10 16 4 5 50MM + - 5 - 2.2 6 9 3 3 35 + -
IAS 4 4 3 2 16mm + - - 2 0 1 1 1 12 - -
MTX 15MG 8 10 4 5 7 + - 2 1.8 5 8 2 3 21 - -
MTX15MG 8 8 4 5 35mm + - 3 4.2 2 2 2 2 12 - -
MTX - - 3 3 5mm - - 1 5 - - - 3 3 13 - -
MTX 20 24 5 5 59MM + - 4 3.6 10 18 5 4 41 + -
MTX 4 4 3 3 44MM + - 9 12.2 1 1 1 1 23 + -
MTX 3 3 3 3 6mm - 4TH TOE - - 1.8 LOST FOLLOWUP
MTX 12 15 4 5 67MM + 2nd toe 4 - 13.2 4 8 2 2 44 + +
MTX 14 18 4 5 87mm + - 7 - 5.4 6 8 3 3 32MM + -
MTX 8 12 3 4 65MM + - 8 20 5 8 4 4 32MM + -
MTX 14 17 4 5 50MM + 4th toe 2 - 1.2 6 10 4 3 34MM + -
MTX 8 11 3 4 43MM + - - - 1.6 6 10 4 4 43MM + -
MTX 12 16 4 5 70MM + 2nd toe - - 1.2 4 5 2 3 43MM + -
MTX 20 22 4 5 76MM + - 8 - 7.2 13 15 5 5 45MM + -
MTX 6 8 3 3 40MM + - 2 - 7.6 5 7 3 3 32MM - -
MTX 8 12 4 3 54MM + - 3 - 5.2 5 9 4 3 43MM - -
MTX 10 11 4 4 80MM + - 2 - 4.4 12 14 5 5 65MM + -
MTX 8 11 4 4 67MM + - 7 - 21.2 5 15 5 4 54MM - -
MTX 12 17 5 4 40mm + - - - 7 LOST FOLLOWUP
MTX 20 26 5 5 70mm + 2nd finger 2 - 1.2
MTX 12 16 5 4 29MM + - 3 - 12 3 8 3 2 21mm - -
MTX 8 10 5 5 50mm + 4th toe 10 - 32.2 4 8 3 3 49mm + +
MTX 14 16 4 4 19mm - - 2 - 1.2 4 10 3 2 24mm - -
MTX+SSZ 7 9 4 4 5mm + - 2 2.5 4.1 4 4 2 2 12mm - -
MTX 4 4 4 4 43mm + - 8 - 3.4 3 5 2 3 23mm - -
MTX 7 9 5 4 60mm + - 6 - 12.2 8 12 3 4 45mm - -
MTX 14 16 5 5 35mm + - 3 - 4.2 9 11 4 3 32mm - -
MTX 14 15 5 4 48mm + - 3 - 1.6 8 9 3 3 21mm - -
MTX - 4 5 5 31mm + - 3 6.5 1
MTX 7 8 4 3 35mm - - - - 1 4 8 3 4 31mm - -
MTX 8 10 5 4 76mm + - 4 5 - 4 6 3 3 43mm + -
MTX 14 17 5 5 80mm + - 4 - 1.2
MTX 10 13 5 4 28mm + 4th toe 4 - 4.8 8 11 4 4 54mm + -
.TKR,mtx 6 8 5 5 60mm + 4th toe 6 6.5 12.2 4 5 4 3 50mm + -
MTX 8 9 4 4 65mm + - 8 - 12
MTX 7 12 5 5 65MM + 1great toe 7 6.5 21.2
MTX 14 16 5 4 27mm + - 4 - 2 6 11 4 5 26mm + -
MTX 4 4 3 4 50mm + 1 - 3.2 5 7 4 4 25mm + -
MTX 11 13 4 4 58mm + - - - 3.8 8 10 4 4 23mm - -
MTX 9 11 4 4 50mm + 2 2 - 1.2 6 8 4 3 24mm - -
SSZ - 4 4 4 34MM - - 2 5.5 1.6 - 2 2 2 16mm - -
MTX 4 4 4 3 15MM _ - 6 - 9.2 4 7 3 3 29MM - 1
At Entry AT 1 YEAR
DMARD 66 SJC68 TJC PGA PtGA ESR CRP Dacty MASES BASDAI PASI 66 SJC 68 TJC PGA PtGA ESR CRP Dacty
At Entry AT 1 YEAR
MTX 12 14 4 4 46mm + - 5 - 1.2 3 8 2 2 32mm + -
MTX 2 6 5 4 10mm - - 8 6 4 1 3 3 2 21mm - -
MTX 15 18 5 5 83mm + - 2 - 4.6 5 8 3 2 31mm + -
- 2 2 5 4 43mm + - - - -
MTX 3 4 4 3 30mm + 1 2 - 1.1 4 4 4 3 18mm + 1
MTX 12 15 5 4 70MM + - 4 - 6.8 5 8 3 3 43mm + -
MTX 15 18 5 4 68MM + - 4 - 5.2 9 12 4 3 45mm + -
MTX 18 18 5 5 69MM + 2 9 6 21.1 10 12 4 3 43mm - 3
MTX 3 4 4 3 41mm - 1 4 - 19.4 2 3 2 2 21mm - 3
MTX 8 14 5 4 55mm + 1 2 - 1.6 6 7 4 4 65mm + -
MTX 9 11 4 4 32mm + - 2 - 4.2 4 6 3 2 - - -
MTX 6 10 4 4 65MM + - 3 - 4.4 2 6 3 2 29MM - -
ETA 12 15 5 5 100MM + - 7 7 14.4 5 5 4 3 76mm + -
MTX 11 16 5 5 60MM + - 8 - 11.2 4 8 3 3 42mm + -
MTX 4 4 4 4 50mm + - 2 - 2.2 4 4 3 2 38mm + -
MTX 8 7 4 4 28mm + - 4 - 4 4 6 3 2 30mm + -
MTX 5 8 3 5 24mm + - 4 - 7.2 3 3 2 2 27mm - -
MTX 9 11 4 4 39 + - 5 - 9.6
MTX 13 15 5 5 130mm + - 2 - 3.6 5 7 3 3 65mm - -
MTX 8 10 5 4 56MM + - 2 - 2.2 4 5 3 3 27mm - -
MTX 3 4 3 4 23MM - - 1 - 1.2 2 5 3 3 24MM - -
INF-3DOS - - 4 5 41MM + - 3 6.5 0.6LOST FOLLOWUP
MTX 9 10 4 4 18mm + - 3 - 4.2 6 8 3 2 18mm - -
MTX 8 14 5 4 38MM + - 3 4.5 2.8 4 5 3 3 19mm + -
MTX 8 12 4 5 54MM - 1 - - 9.2 6 10 4 4 43MM - -
MTX 13 16 5 5 60mm - lt 4th toe 2 - 11.2 4 5 3 2 34mm - -
MTX 3 3 3 3 60mm + - 5 - 4 5 6 5 4 39MM + -
MTX 8 9 4 3 28mm - 4th fing 2 - 0.8 6 9 2 3 31mm - -
MTX 8 10 5 4 36mm + - 7 6 2.4
MTX 2 4 4 4 15MM + 1 4 4.5 0.9
IAS 2 4 3 3 31mm + - - - -
MTX 9 11 4 5 37MM + - 7 - 9.2
MTX 6 9 3 4 45MM + - 4 - 6.4
MTX 7 10 4 4 46MM + - 4 - 7.6
MTX 9 11 4 4 40MM + - - - 5.4
MTX 8 10 4 4 54mm + - 4 - 4.2 5 4 3 3 23mm - -
MTX 3 3 3 3 10mm - - 1 - 1.2
MTX 12 14 4 5 60MM + - 7 - 9.2 6 7 2 2 15mm - -
MTX 6 8 4 5 25mm + - 2 - 4.2
SSZ - - 3 5 27MM + - 4 5.5 4.8
ETANERC 2 4 5 5 60mm + - 6 6.5 2.2 2 4 3 3 35mm - -
MTX 8 9 4 5 46MM + - 8 - 7.4 4 5 2 3 21mm - -
MTX 8 10 5 5 60mm + - 2 - 2.2
MTX 3 4 3 5 49MM 1 6 - 7.8 3 4 3 4 31MM - -
- 4 6 5 5 77mm + - 6 7 12.4 3 4 4 5 51mm + -
DMARD 66 SJC68 TJC PGA PtGA ESR CRP Dacty MASES BASDAI PASI 66 SJC 68 TJC PGA PtGA ESR CRP Dacty
At Entry AT 1 YEAR
MTX 7 9 4 4 40mm + - 3 - 7.6 - - - - - - -
MTX 6 6 4 5 19mm - - 3 - 3.6
MTX 4 4 3 4 5mm+ + - 2 - 9.2
MTX 3 4 4 5 4mm - 1 7 - 12.2
MTX 4 4 3 5 60mm + - 4 - 7.6
MTX 13 15 5 5 65mm + - 3 - 2.6
MTX 8 9 4 4 35MM + - 4 - 2.2
MTX 12 14 5 4 34MM + - 4 - 2.2
MTX 11 16 5 5 30MM + - 2 - 1
MTX 12 12 5 5 62MM - - 4 - 4,0
MTX 3 4 5 5 90mm + - 6 6.5 8
ETARNER - - 5 5 125MM + - 2 6.6 0.4
MTX 3 3 4 4 52mm + - 3 5.5 2.4
MTX 2 6 3 4 48MM + - 5 6 1.4
- 3 2 4 4 25mm + - 4 - 0.7
MTX 8 11 4 5 46MM + - 4 - 6.2
NSAIDS - 2 2 3 29MM - - 4 - 1.6
MTX 3 4 3 3 27MM - - 4 - 1.9
ETA+CYC 6 12 5 5 58MM + - 8 5 36.8
ETA 8 8 5 5 45MM + 1 1 - 1.2
MASES BASDAI OUTCOME 66 SJC 68 TJC PGA PtGA ESR CRP Dacty MASES BASDAI OUTCOME
- PSARC - 1 1 1 24MM - - - - PSARC
- PSARC 2 5 3 3 26MM - - - - PSARC
- PSARC 6 8 4 5 43MM - - 3 - FLARE
- PSARC - 1 1 1 8mm - - - - MDA
- PSARC LOST LOST LOST
- PSARC 2 4 2 2 23MM - - - - PSARC
5
4 PSARC
- PSARC
LOST
1 PSARC 2 4 3 2 23MM - - PSARC
4 PSARC 1 4 2 1 43MM - - - - PSARC
- - 3 9 4 4 34MM - - PERSIST
- PSARC 2 4 2 2 32MM - - - - PSARC
- -
- PSARC 2 6 2 2 23MM - - - - PSARC
- - 12 14 5 5 65MM + - - - PERSIST
- - 4 9 5 4 49MM - - - - PERSIST
- - 4 5 3 3 32MM - - - - PSARC
3 - FLARE 13 15 5 5 54MM + - - - FLARE
2 - PERSIST 7 12 5 4 53MM + - - - PERSIST
LOST
LOST
2 - PSARC 2 5 2 1 12mm - - - - PSARC
2 - - 7 11 4 5 55MM + + - - PERSIST
- - PSARC 2 5 2 2 20mm - - - - PSARC
1 2 PSARC 1 3 2 1 11mm - - 3 - PSARC
1 - PERSIST 4 8 4 3 21mm - - - - POLY
- - PERSIST 3 4 3 2 39mm - - - - PSARC
- - PSARC 1 3 2 2 26MM + - - - PSARC
- - PSARC 2 5 2 2 19mm - - - - PSARC
LOST
- - PERSIST 8 8 4 4 45MM + - - - FLARE
- 4 PSARC 2 5 2 2 32mm - - - 4 PSARC
LOST
- - PERSIST 7 7 3 4 32mm + - - - PSARC
2 6 PSARC 2 5 3 3 34mm + - - 6 PSARC
LOST
LOST
- - FLARE 3 5 3 2 21mm + - - - PSARC
- - POLY 4 8 4 4 39MM + - - - P0LY
- - PSARC
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A STUDY ON CLINICO- IMMUNOLOGICAL PROFILE AND TREATMENT OUCOME OF
PSORIATIC ARTHRITIS AIMS AND OBJECTIVES 1) To study the clinical profile of patients with
psoriatic arthritis. 2) To assess the correlation between skin disease and arthritis in patients with
psoriatic arthritis. 3) To study the immunological profile of patients with psoriatic arthritis. 4) To
assess the outcome of patients with psoriatic arthritis. INTRODUCTION: Robert Willan, the British
dermatologist described psoriasis as an independent disease in 18-th century.1The French Physician
Baron Jean Louis Alibert first described the association between the psoriasis and psoriatic arthritis
in 1918. 2 Initial clinical features of...
Copyright 2012 Turnitin. All rights reserved.
 
